Pfizer's discontinuation of emprumapimod leaves an unmet need

Based on an interim futility analysis of its global Phase III trial, REALM-DCM, US pharma giant Pfizer (NYSE: PFE) recently ceased clinical trial development of its therapy emprumapimod (PF-07265803). The drug was meant to target dilated cardiomyopathy (DCM) patients whose condition was due to a lamin gene mutation.

According to sector analytics firm GlobalData’s report, ‘ Cardiomyopathies – Global Drug Forecast and Market Analysis to 2031’, emprumapimod was not expected to significantly contribute to cardiomyopathy drug sales over the 10-year forecast period.

Pharmaceutical analyst Sarah Bundra commented: “The number of patients who have developed DCM as a result of the mutation of the lamin gene is comparatively small, and as such, emprumapimod was not expected to capture a significant portion of patient shares.”